SGO meeting Tuesday

Here are the top tweets from the SGO meeting on Tuesday!  

Treating the Whole Patient

If no one talks about it, we aren’t treating the WHOLE patient. Break through the barriers. Sexual health is part of our responsibility as female health providers. #SGOmtg #SGOHawaii50 pic.twitter.com/vsotOJjxoZ

— Kristin Koerten (@KMKoerten) March 19, 2019

Patient Perspective on Clinical Trials

Yes- Thank-you Mary for educating us re patients’ concerns. So important for us as we design #clinicaltrials! #sgomtg @gyncsm https://t.co/H9nLSFC2JI

— Bhavana Pothuri (@BPothuri) March 19, 2019

 Maintenance Olaparib

Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in iBRCA/i-Mutant Ovarian Cancer #SGOMtg https://t.co/Rm4QL3GoD1

— SGO (@SGO_org) March 19, 2019

GAS6 and chemoresistance

#SGOMtg learns increased GAS6 assoc w/ #chemoresistance & lower #PFS in patients w/ high-grade #OvarianCancer

Chemo + anti-GAS6 AVB-500 decreases #tumor burden, tumor & stromal cell viability in mouse #PDX #modelhttps://t.co/7aGWxrQUsR#oncology #immunotherapy #antibody pic.twitter.com/IMZo1s0rrO

— DDNews Online (@DDNewsOnline) March 19, 2019

Immunotherapy

Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02). #SGOMtg https://t.co/HZEMOBK9Bj

— SGO (@SGO_org) March 19, 2019

Wonderful distillation of immunotherapy session by @KunleOdunsiMD of @RoswellPark including where research needs to go in future. Biomarkers predicative of response needed! #sgomtg #gyncsm pic.twitter.com/azdssh7opw

— Annie Ellis (@Stigetta) March 19, 2019

Dr. Cibula presents survival analysis of SOV02 Dendritic Cell Vaccine in ovarian cancer #sgomtg #gyncsm pic.twitter.com/Rw7ZwceAWq

— Annie Ellis (@Stigetta) March 19, 2019

Cisplatin/Gemzar/Pembrolizumab

#SGOmtg Cis/gem/pembro tolerable, but no durable response in platinum-R #ovariancancer. Unfortunately another study showing limited efficacy of #checkpointinhibitors in ovarian cancer.… https://t.co/Hd7oUN7Lz9

— Deanna Teoh, M.D., M.S., FACOG, FACS (@DeannaTeoh) March 19, 2019

Next year's meeting is in Toronto. And the gavel has passed to Dr Huh!

Proud & Honored to “pass the gavel” of leadership to
Dr. Warner Huh , 51st President of SGO at #SGOmtg . Welcome Dr Huh -a Courageous Warrior in our Fight to Eradicate GYN Cancer ! pic.twitter.com/UcpNL9dJRU

— Carol Brown (@drcarolbrownMSK) March 19, 2019

Thank you to  @KMKoerten , @Stigetta, @DeannaTeoh , @drcarolbrownMSK , @SGO_org, @DDNewsOnline, @BPothuri for tweeting from the meeting!


Dee
Every Day is a Blessing!